<DOC>
	<DOCNO>NCT01232569</DOCNO>
	<brief_summary>This randomize , parallel-group , placebo-controlled , multicenter study evaluate reduction disease activity safety tocilizumab ( RoActemra/Actemra ) combination traditional disease-modifying anti-rheumatic drug ( DMARDs ) patient active , moderate severe rheumatoid arthritis . In double-blind part study , patient randomize receive either 162 mg tocilizumab placebo subcutaneously every 2 week 24 week use pre-filled syringe . In open-label part study , patient randomize receive 162 mg tocilizumab subcutaneously every 2 week Week 24 Week 96 use pre-filled syringe auto-injector .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Given Subcutaneously Combination With Traditional DMARDs Patients With Moderate Severe Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adult patient , ≥ year age . Moderate severe rheumatoid arthritis ≥ 6 month duration . Receiving treatment outpatient basis . Swollen joint count ( SJC ) ≥ 6 ( 66 joint count ) tender joint count ( TJC ) ≥ 8 ( 68 joint count ) screen study start . On stable dose diseasemodifying antirheumatic drug least 8 week prior study start . Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow randomization . Rheumatic autoimmune disease rheumatoid arthritis , Secondary Sjögren 's Syndrome rheumatoid arthritis allow . Functional class IV define American College Rheumatology ( ACR ) Classification Functional Status Rheumatoid Arthritis . Diagnosis juvenile idiopathic arthritis juvenile rheumatoid arthritis and/or rheumatoid arthritis age 16 year . Prior history current inflammatory joint disease rheumatoid arthritis . History malignancy , active recurrent infection , positive hepatitis B surface antigen hepatitis C antibody , active tuberculosis , serious allergy biologics , history diverticular disease symptomatic GI condition might predispose perforation . Other inclusion exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>